CARDIFF ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
CARDIFF ONCOLOGY, INC. (CRDF) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number of 3.30 million shares as of 2012-09-30, per its 10-Q filed 2012-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber · last filed 2012-11-14
- 2012-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 3.30M shares.
- 2012-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 3.06M shares.
- 2011-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2.43M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number |
|---|---|
| 2012-09-30 | 3.30M shares 10-Q · filed 2012-11-14 |
| 2012-06-30 | 3.06M shares 10-Q · filed 2012-08-14 |
| 2011-12-31 | 2.43M shares 10-Q · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |